Codon-Optimized rAAV Vectors for CYP4V2 Expression in BCD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Bietti Crystalline Dystrophy (BCD) face limitations due to inefficient and unsafe delivery methods, lacking effective human translatable animal models, and the need for improved expression of the CYP4V2 gene to treat the disease effectively.
Innovation Solution
Development of recombinant adeno-associated virus (rAAV) vectors containing codon-optimized CYP4V2 sequences combined with specific gene expression regulatory elements, such as the CAG promoter, SV40 polyA, and WPRE, to enhance transgene expression levels up to 26.1 times compared to wild-type sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If wild-type CYP4V2 coding sequence is used in gene therapy vectors, then the treatment approach is simpler, but the transgene expression level is insufficient
Solution Approach 1:
The patent applies codon optimization to the CYP4V2 coding sequence, changing the nucleotide parameters while maintaining the amino acid sequence. This optimization of codon usage parameters significantly enhances translation efficiency and protein expression levels, resolving the contradiction between construct simplicity and expression productivity
Solution Approach 2:
The patent combines multiple regulatory elements (CAG promoter, WPRE, SV40 polyA signal) with the codon-optimized CYP4V2 coding sequence to create a composite expression cassette. This composite construct integrates multiple functional components that work synergistically to achieve high-level, sustained transgene expression while maintaining a relatively simple overall structure
2Reliability
If basic AAV vector delivery is used, then the delivery method is safer and simpler, but the therapeutic effect is limited due to insufficient gene expression
Solution Approach 1:
The patent optimizes the coding sequence parameters through codon optimization and combines it with strong regulatory elements (CAG promoter with WPRE), transforming a basic AAV vector into a high-expression system while maintaining the inherent safety advantages of AAV delivery
Solution Approach 2:
The patent performs preliminary optimization of the transgene construct (codon optimization, regulatory element selection) before AAV packaging, ensuring that the vector is pre-configured for maximum expression potential. This preliminary preparation of the genetic cassette ensures high therapeutic effect while maintaining AAV safety profile
Data Source
AI summary
The present disclosure provides a recombinant adeno-associated vector comprising a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences and its use in treating Bietti Crystalline Dystrophy (BCD).